*October 2023* The European Commission (EC) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.1 The regulatory decision was supported by data from the phase…

*October 2023* Take home message: Amivantamab in combination with chemotherapy showed significantly improved PFS and a higher response rate compared to chemotherapy alone in treatment-naive patients with advanced non-small-cell lung cancer harboring EGFR exon 20 insertions, demonstrating its efficacy as a first-line treatment. The phase 3 PAPILLON trial (NCT04538664) resulted in…

*October 2023* Osimertinib (Tagrisso) plus chemotherapy reduced the risk of central nervous system (CNS) disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer (NSCLC) who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial (NCT04035486) presented…

*October 2023* Take home message: In 1L setting, combo of Amivantamab (ami), an EGFR-MET bispecific antibody, and Lazertinib (laz), a CNS-penetrant 3rd-generation EGFR TKI, was evaluated against Osimertinib (osi) in the MARIPOSA study (NCT04487080) for treatment-naïve, EGFR-mutated locally advanced or metastatic NSCLC. After a median follow-up of 22.0 months, ami+laz…

*September 2023* RARITAN, N.J., Sept. 28, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), in combination with lazertinib, an oral third-generation EGFR tyrosine kinase…

*September 2023* "Insanity is doing the same thing over and over again and expecting different results." While there's some debate as to who actually said that off-quoted comment, there's less uncertainty about the kernel of truth it contains. When it comes to treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung…

*October 2023* Findings from the FLAURA2 study, presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, showed that chemotherapy added to osimertinib in the first-line setting significantly increased progression-free survival (PFS) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, without data…

*September 2023* Expert Stephen Liu, MD, joins the Oncology Brothers to share insight into updated data from the FLAURA2 trial of osimertinib with or without chemotherapy in patients with metastatic non–small cell lung cancer. Watch video here.